Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2730 | GCLM | Dong_P5 | Human | Prostate | Tumor | 1.45e-33 | -6.94e-01 | 0.053 |
2730 | GCLM | Dong_P6 | Human | Prostate | Tumor | 1.44e-05 | -6.80e-01 | 0.0371 |
2730 | GCLM | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 3.75e-02 | -8.03e-01 | 0.1531 |
2730 | GCLM | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 1.40e-05 | -7.04e-01 | 0.1633 |
2730 | GCLM | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 2.71e-07 | -6.44e-01 | 0.1608 |
2730 | GCLM | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 5.81e-03 | -6.52e-01 | 0.1604 |
2730 | GCLM | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 1.53e-03 | -6.60e-01 | 0.1621 |
2730 | GCLM | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 8.77e-09 | -7.51e-01 | 0.1602 |
2730 | GCLM | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 1.26e-12 | -7.26e-01 | 0.1575 |
2730 | GCLM | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 2.35e-12 | -6.05e-01 | 0.1545 |
2730 | GCLM | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 1.24e-11 | -7.40e-01 | 0.1569 |
2730 | GCLM | P1_S1_AK | Human | Skin | AK | 4.03e-03 | 2.62e-01 | -0.3399 |
2730 | GCLM | P5_S10_cSCC | Human | Skin | cSCC | 1.65e-04 | 2.08e-01 | -0.299 |
2730 | GCLM | P1_cSCC | Human | Skin | cSCC | 3.93e-05 | 4.62e-01 | 0.0292 |
2730 | GCLM | P2_cSCC | Human | Skin | cSCC | 1.69e-10 | 5.21e-01 | -0.024 |
2730 | GCLM | P4_cSCC | Human | Skin | cSCC | 6.00e-13 | 4.54e-01 | -0.00290000000000005 |
2730 | GCLM | P10_cSCC | Human | Skin | cSCC | 3.36e-38 | 1.32e+00 | 0.1017 |
2730 | GCLM | Adj_PTCwithHT_6 | Human | Thyroid | HT | 5.88e-09 | -2.96e-01 | 0.02 |
2730 | GCLM | Adj_PTCwithHT_8 | Human | Thyroid | HT | 1.30e-02 | -3.08e-01 | 0.0267 |
2730 | GCLM | PTCwithHT_6 | Human | Thyroid | HT | 1.29e-07 | -2.87e-01 | 0.02 |
Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/GCLM_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/GCLM_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GCLM_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GCLM_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GCLM_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/GCLM_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GCLM_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GCLM_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:20012349 | Breast | Precancer | negative regulation of apoptotic signaling pathway | 39/1080 | 224/18723 | 5.35e-10 | 4.77e-08 | 39 |
GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
GO:00086378 | Breast | Precancer | apoptotic mitochondrial changes | 23/1080 | 107/18723 | 3.44e-08 | 2.12e-06 | 23 |
GO:00518816 | Breast | Precancer | regulation of mitochondrial membrane potential | 18/1080 | 74/18723 | 1.45e-07 | 7.82e-06 | 18 |
GO:19012149 | Breast | Precancer | regulation of neuron death | 41/1080 | 319/18723 | 1.27e-06 | 4.80e-05 | 41 |
GO:00435237 | Breast | Precancer | regulation of neuron apoptotic process | 31/1080 | 212/18723 | 1.69e-06 | 6.08e-05 | 31 |
GO:20012369 | Breast | Precancer | regulation of extrinsic apoptotic signaling pathway | 24/1080 | 151/18723 | 5.78e-06 | 1.70e-04 | 24 |
GO:00075688 | Breast | Precancer | aging | 41/1080 | 339/18723 | 5.95e-06 | 1.71e-04 | 41 |
GO:00971919 | Breast | Precancer | extrinsic apoptotic signaling pathway | 30/1080 | 219/18723 | 9.42e-06 | 2.50e-04 | 30 |
GO:00342849 | Breast | Precancer | response to monosaccharide | 29/1080 | 225/18723 | 4.19e-05 | 9.00e-04 | 29 |
GO:00097439 | Breast | Precancer | response to carbohydrate | 31/1080 | 253/18723 | 6.15e-05 | 1.25e-03 | 31 |
GO:00425938 | Breast | Precancer | glucose homeostasis | 31/1080 | 258/18723 | 8.89e-05 | 1.69e-03 | 31 |
GO:00335008 | Breast | Precancer | carbohydrate homeostasis | 31/1080 | 259/18723 | 9.56e-05 | 1.79e-03 | 31 |
GO:20012379 | Breast | Precancer | negative regulation of extrinsic apoptotic signaling pathway | 16/1080 | 97/18723 | 1.29e-04 | 2.24e-03 | 16 |
GO:00097469 | Breast | Precancer | response to hexose | 27/1080 | 219/18723 | 1.61e-04 | 2.69e-03 | 27 |
GO:00316679 | Breast | Precancer | response to nutrient levels | 47/1080 | 474/18723 | 2.09e-04 | 3.27e-03 | 47 |
GO:00094108 | Breast | Precancer | response to xenobiotic stimulus | 45/1080 | 462/18723 | 4.17e-04 | 5.56e-03 | 45 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GCLM | SNV | Missense_Mutation | novel | c.295N>C | p.Glu99Gln | p.E99Q | P48507 | protein_coding | tolerated(0.47) | benign(0.072) | TCGA-OL-A5RZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
GCLM | insertion | Nonsense_Mutation | novel | c.502_503insTAAACTTTAATCACTGTGGATTGTGATTTTTC | p.Asp168ValfsTer9 | p.D168Vfs*9 | P48507 | protein_coding | | | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GCLM | SNV | Missense_Mutation | | c.226C>T | p.His76Tyr | p.H76Y | P48507 | protein_coding | deleterious(0.01) | benign(0.278) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GCLM | SNV | Missense_Mutation | novel | c.133G>A | p.Asp45Asn | p.D45N | P48507 | protein_coding | deleterious(0) | benign(0.273) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
GCLM | SNV | Missense_Mutation | rs773867359 | c.383N>T | p.Ala128Val | p.A128V | P48507 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
GCLM | SNV | Missense_Mutation | | c.635T>C | p.Leu212Ser | p.L212S | P48507 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GCLM | SNV | Missense_Mutation | rs761296185 | c.716N>T | p.Ala239Val | p.A239V | P48507 | protein_coding | tolerated(0.27) | benign(0) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
GCLM | SNV | Missense_Mutation | novel | c.820T>C | p.Ser274Pro | p.S274P | P48507 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GCLM | SNV | Missense_Mutation | novel | c.815G>T | p.Arg272Met | p.R272M | P48507 | protein_coding | tolerated_low_confidence(0.06) | benign(0.044) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
GCLM | SNV | Missense_Mutation | | c.523C>A | p.Leu175Met | p.L175M | P48507 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |